We are live on ! Find out more
CCXI icon

ChemoCentryx

Delisted

CCXI was delisted on the 19th of October, 2022.

87 hedge funds and large institutions have $141M invested in ChemoCentryx in 2017 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 31 increasing their positions, 25 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

112% more call options, than puts

Call options by funds: $165K | Put options by funds: $78K

24% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 25

17% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 6

1% more funds holding

Funds holding: 86 → 87 (+1)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0.4% less ownership

Funds ownership: 48.96% → 48.56% (-0.4%)

18% less capital inflows, than outflows

Capital inflows: $5.96M | Capital outflows: $7.23M

Holders
87
Holders Change
+1
Holders Change %
+1.16%
% of All Funds
1.97%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
7
Increased
31
Reduced
25
Closed
6
Calls
$165​K
Puts
$78​K
Net Calls
+$87​K
Net Calls Change
-⁠$114​K

CCXI Hedge Fund Activity: Q4 2017 in Review

87 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in ChemoCentryx (CCXI) for Q4 2017, worth a combined $141M — down 20% from $177M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new CCXI positions and 6 closed out — a net gain of 1 holder — while 31 added to existing stakes and 25 trimmed.

The largest buyer was Nantahala Capital Management, adding an estimated $1.83M. The largest seller was Iguana Healthcare Management, cutting an estimated $1.2M.

  • 87 institutional investors held ChemoCentryx (CCXI) as of Q4 2017, up from 86 in Q3 2017.
  • Funds reported $141M of ChemoCentryx stock for Q4 2017, down 20% quarter-over-quarter.
  • 7 funds opened new ChemoCentryx positions in Q4 2017 and 6 closed out, a net change of +1 holder.
  • The largest ChemoCentryx buyer in Q4 2017 was Nantahala Capital Management, an estimated $1.83M added.
  • The largest ChemoCentryx seller in Q4 2017 was Iguana Healthcare Management, an estimated $1.2M sold.

Based on aggregated 13F filings for Q4 2017.